Monitoring side effects of radiotherapy in metastatic cancer patients using wearable technology
Patient Reported Outcomes/Metrics Program Trial - Palliative Radiation
This study is testing if a wearable device can help track vital signs and activity levels in patients with metastatic cancer undergoing radiotherapy to better manage side effects and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT04983199 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit 100 patients undergoing palliative radiotherapy for metastatic cancer to wear the Hexoskin Medical System. The study will assess the feasibility of using this wearable technology to monitor vital signs and activity levels, which may help in the early detection and management of radiotherapy-related side effects. By combining objective data with patient-reported outcomes, the study seeks to enhance the evaluation of treatment effects and improve patient care. Participants will also complete questionnaires to provide insights into their quality of life and pain management.
Who should consider this trial
Good fit: Ideal candidates include patients with a known cancer diagnosis who are scheduled to receive palliative radiotherapy and can use the Hexoskin Medical Shirt.
Not a fit: Patients receiving whole brain radiotherapy, those with major cognitive impairments, or those with certain medical devices like pacemakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of side effects from radiotherapy, enhancing the quality of life for patients with metastatic cancer.
How similar studies have performed: While the use of wearable technology in monitoring health outcomes is gaining traction, this specific approach in the context of palliative radiotherapy is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Planned to receive palliative radiotherapy for pain * Known cancer diagnosis * Able to wear Hexoskin Medical Shirt * Ability to use and populate the mobile app (Zamplo) with or without assistance * ECOG: 0-3 * Willing to provide a list of analgesic (pain relief) medication * Willing to complete questionnaires * Life expectancy of at least 3 months Exclusion Criteria: * Receiving whole brain radiotherapy * Major cognitive or psychiatric impairments * Pregnant women * Allergies to: polyester, synthetic fibers * Patients with pacemakers or implantable cardioverter-defibrillator (ICD) * Patients on a Holter Monitor
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Philip Wong — The Princess Margaret Cancer Foundation
- Study coordinator: Philip Wong
- Email: philip.wong@rmp.uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.